文献速递妇科肿瘤

铂敏感复发性卵巢癌的二次肿瘤细胞减灭术:一项Meta分析

Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis.
PubMed 文献 · J Clin Oncol · 2022-02-21

该Meta分析纳入1983至2021年MEDLINE、EMBASE和Cochrane图书馆的80项合格研究,其中36项研究2805例患者报告死亡率,汇总死亡率为44.2%(95%CI 39.0至49.5),完全和满意肿瘤细胞减灭均与更好生存结局相关(P<.001和P=.005),二次肿瘤细胞减灭术实现最大程度肿瘤切除可显著延长总生存。

要点

  • 36项研究2805例铂敏感复发性卵巢癌患者汇总死亡率为44.2%(95%CI 39.0至49.5)。
  • 完全和满意肿瘤细胞减灭均为显著调节因素,与更好生存结局相关(P<.001和P=.005)。
  • 完全和满意肿瘤细胞减灭比例每增加10%,中位总生存分别延长8.97%和7.04%。

核心结论

  • 二次肿瘤细胞减灭术实现最大程度肿瘤切除可显著延长铂敏感复发性卵巢癌患者的总生存。

研究设计与样本

  • 从MEDLINE、EMBASE和Cochrane图书馆检索1983至2021年发表的符合纳入标准的研究。
  • 80项合格研究中36项报告死亡率的研究(共2805例患者)纳入Meta分析。
  • 以死亡率为主要结局整合单臂研究效应量,采用Meta回归评估完全和满意肿瘤细胞减灭对生存的影响。
  • 对对数转换的中位总生存时间以研究规模为权重进行线性回归模型分析(基于57项研究)。

主要发现

  • 汇总死亡率为44.2%(95%CI 39.0至49.5)。
  • 完全和满意肿瘤细胞减灭均为显著调节因素,与更好生存结局相关(P<.001和P=.005)。
  • 完全和满意肿瘤细胞减灭比例每增加10%,中位总生存时间分别增加8.97%和7.04%(调整其他变量后)。
  • Egger检验提示无发表偏倚(P=.327),排除14项研究后的敏感性分析显示相似结果。

关键数值与推荐

  • 异质性检验Cochrane Q检验P<0.0001,Higgins I²=86%,采用随机效应模型。
  • 汇总死亡率44.2%(95%CI 39.0至49.5)。
  • 完全肿瘤细胞减灭作为调节因素P<.001,满意肿瘤细胞减灭作为调节因素P=.005。
  • Egger检验P=.327。
  • 完全和满意肿瘤细胞减灭比例每增加10%,中位总生存时间分别增加8.97%和7.04%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 存在强异质性,Cochrane Q检验P<0.0001,Higgins I²=86%。
  • 14项研究位于漏斗图外。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The survival impact of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer was studied. METHODS: We identified published studies from 1983 to 2021 following our inclusion criteria from MEDLINE, EMBASE, and Cochrane library. To integrate the effect size of single-arm studies, meta-analysis was performed using death rate as a primary outcome. The effect of complete cytoreduction and optimal cytoreduction on survival was evaluated using meta-regression. The pooled death rate was presented with a 95% CI. The publication bias was evaluated with the funnel plot and Egger's test, and sensitivity analysis was performed. To overcome missing death rates, the linear regression model was performed on log-transformed median overall survival (OS) time using study size as a weight. RESULTS: Thirty-six studies with 2,805 patients reporting death rates were used for this meta-analysis of the 80 eligible studies. There was strong heterogeneity, with the P value of the Cochrane Q test of < 0.0001 and Higgins's I2 statistics of 86%; thus, we considered a random effect model. The pooled death rate was 44.2% (95% CI, 39.0 to 49.5), and both the complete and optimal cytoreductions were associated with better survival outcomes as significant moderators in the meta-regression model (P < .001 and P = .005, respectively). Although 14 studies were located outside the funnel plot, Egger's test indicated no publication bias (P = .327). A sensitivity analysis excluding 14 studies showed similar results. In the linear regression model on the basis of 57 studies, the median OS time increased by 8.97% and 7.04% when the complete and optimal cytoreduction proportion increased by 10%, respectively, after adjusting other variables. CONCLUSION: Secondary cytoreductive surgery, resulting in maximal tumor resection, significantly prolongs OS in platinum-sensitive recurrent ovarian cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Baek MH, Park EY, Ha HI, et al. Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis. J Clin Oncol. 2022. PMID: 35188810. doi:10.1200/JCO.21.02085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。